Note 1 - Summary of Business

12 Months Ended

Dec. 31, 2020

Notes to Financial Statements

Business Description and Basis of Presentation [Text Block]

( 1 ) Summary of Business

(a) Description of Business

BioCardia, Inc. (BioCardia or the Company), is a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular and respiratory diseases with significant unmet medical needs. The Company's lead therapeutic candidate is the CardiAMP® Cell Therapy System, which provides an autologous bone marrow derived cell therapy using a patient's own cells for treatment in

two

clinical indications: heart failure that develops after a heart attack and chronic myocardial ischemia. The Company's

second

therapeutic platform is the investigational culture expanded bone marrow derived allogeneic “off the shelf” Neurokinin-

1

Receptor Positive mesenchymal stem cells for the treatment of cardiac and pulmonary disease. To date, the Company has devoted substantially all its resources to research and development efforts relating to its therapeutic candidates and biotherapeutic delivery systems including conducting clinical trials, developing manufacturing and sales capabilities, in-licensing related intellectual property, providing general and administrative support for these operations and protecting its intellectual property. 

BioCardia also has

three

enabling device product lines: (

1

) the CardiAMP cell processing system; (

2

) the Helix biotherapeutic delivery system, or Helix; and (

3

) the Morph vascular access product line, or Morph. The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.